Rucaparib population pharmacokinetics (PPK) and exposure-response (ER) analyses in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2

被引：2

作者：

Chowdhury, S. ^{[1
,2
]}

Patnaik, A. ^{[3
]}

Campbell, D. ^{[4
]}

Shapiro, J. ^{[5
]}

Bryce, A. H. ^{[6
]}

McDermott, R. ^{[7
]}

Sautois, B. ^{[8
]}

Vogelzang, N. J. ^{[9
]}

Bambury, R. ^{[10
]}

Voog, E. ^{[11
]}

Zhang, J. ^{[12
]}

Green, M. ^{[13
]}

Beltman, J. ^{[14
]}

Despain, D. ^{[15
]}

Simmons, A. D. ^{[16
]}

Watkins, S. P. ^{[17
]}

Golsorkhi, A. ^{[18
]}

Xiao, J. ^{[19
]}

Abida, W. ^{[20
]}

机构：

[1] Guys Hosp, Med Oncol, London, England

[2] Sarah Cannon Res Inst, London, England

[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA

[4] Univ Hosp Geelong, Barwon Hlth, Med Oncol, Geelong, Vic, Australia

[5] Cabrini Hosp, Med Oncol, Malvern, Australia

[6] Mayo Clin, Hematol & Med Oncol, Phoenix, AZ USA

[7] Adelaide & Meath Hosp Natl Childrens Hosp, Genitourinary Oncol, Dublin, Ireland

[8] CHU Sart Tilman, Liege Univ Hosp, Med Oncol, Liege, Belgium

[9] Comprehens Can Ctr Nevada, Med Oncol, Las Vegas, NV USA

[10] Cork Univ Hosp, Med Oncol, Cork, Ireland

[11] Clin Victor Hugo Ctr Jean Bernard, Med Oncol, Le Mans, France

[12] H Lee Moffitt Canc Ctr & Res Inst, Genitourinary Oncol, Tampa, FL USA

[13] Certara Strateg Consulting, Integrated Drug Dev, Menlo Pk, CA USA

[14] Clovis Oncol Inc, Regulatory Affairs, Boulder, CO USA

[15] Clovis Oncol Inc, Biostat, Boulder, CO USA

[16] Clovis Oncol Inc, Translat Med, Boulder, CO USA

[17] Clovis Oncol UK Ltd, Clin Sci, Cambridge, England

[18] Clovis Oncol Inc, Clin Dev, Boulder, CO USA

[19] Clovis Oncol Inc, Clin & Nonclin Pharmacol, Boulder, CO USA

[20] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.918

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

659P

引用

页码：S533 / S534

页数：2

共 50 条

[1] Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
Abida, W.
Campbell, D.
Patnaik, A.
Sautois, B.
Shapiro, J.
Vogelzang, N. J.
Bryce, A. H.
McDermott, R.
Ricci, F.
Rowe, J.
Zhang, J.
Simmons, A. D.
Despain, D.
Dowson, M.
Golsorkhi, T.
Chowdhury, S.
ANNALS OF ONCOLOGY, 2019, 30 : 327 - +
[2] Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
Loehr, Andrea
Patnaik, Akash
Campbell, David
Shapiro, Jeremy
Bryce, Alan H.
McDermott, Ray
Sautois, Brieuc
Vogelzang, Nicholas J.
Bambury, Richard M.
Voog, Eric
Zhang, Jingsong
Piulats, Josep M.
Hussain, Arif
Ryan, Charles J.
Merseburger, Axel S.
Daugaard, Gedske
Heidenreich, Axel
Fizazi, Karim
Higano, Celestia S.
Krieger, Laurence E.
Sternberg, Cora N.
Watkins, Simon P.
Despain, Darrin
Simmons, Andrew D.
Dowson, Melanie
Golsorkhi, Tony
Chowdhury, Simon
Abida, Wassim
CLINICAL CANCER RESEARCH, 2021, 27 (24) : 6677 - 6686
[3] Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
Abida, W.
Bryce, A. H.
Vogelzang, N. J.
Amato, R. J.
Percent, I.
Shapiro, J. D.
McDermott, R.
Hussain, A.
Patnaik, A.
Petrylak, D.
Ryan, C. J.
Stanton, T.
Zhang, J.
Simmons, A. D.
Despain, D.
Collins, M.
Golsorskhi, T.
Scher, H. I.
Chowdhury, S.
ANNALS OF ONCOLOGY, 2018, 29 : 272 - 272
[4] TRIAL OF RUCAPARIB IN PROSTATE INDICATIONS 2 (TRITON2): AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL PHASE 2 STUDY OF THE PARP INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)
Shapiro, Jeremy
Voskoboynik, Mark
Krieger, Laurence
Byard, Ian
Clay, Timothy
Ganju, Vinod
Abida, Wassim
Chowdhury, Simon
Watkins, Simon
Despain, Darrin
Simmons, Andy
Go, Jowell
Golsorkhi, Tony
Scher, Howard I.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 61 - 61
[5] The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
Chowdhury, S.
Abida, W.
Arranz Arija, J.
Daugaard, G.
Fizazi, K.
Gez, E.
Heidenreich, A.
Joly Lobbedez, F.
McDermott, R.
Merseburger, A. S.
Piulats Rodriguez, J. M.
Sautois, B.
Sridhar, S.
Sternberg, C. N.
Watkins, S.
Simmons, A.
Shetty, S.
Golsorkhi, A.
Ryan, C. J.
Scher, H.
ANNALS OF ONCOLOGY, 2017, 28
[6] TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD)
Heidenreich, A.
Carl, S.
Feyerabend, S.
Gleissner, J.
Gruellich, C.
Heinrich, B.
Merseburger, A.
Miller, K.
Stenzl, A.
Steuber, T.
Wirth, M.
Watkins, S.
Simmons, A.
Go, J.
Golsorkhi, T.
Abida, W.
Scher, H. I.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 75 - 75
[7] Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study
Rao, Arpit
Morris, David
Assikis, Vasily J.
Jha, Gautam Gopalji
Ryan, Charles J.
Ablaza, Adriel-John
Habeck, Jenn
Loehr, Andrea
Xiao Jim
Gangolli, Esha A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[8] TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Abida, Wassim
Bryce, Alan Haruo
Balar, Arjun Vasant
Chatta, Gurkamal S.
Dawson, Nancy Ann
Guancial, Elizabeth A.
Hussain, Arif
Jha, Gautam Gopalji
Lipsitz, David Uri
Patnaik, Akash
Petrylak, Daniel Peter
Ryan, Charles J.
Stanton, Thomas S.
Vogelzang, Nicholas J.
Zhang, Jingsong
Simmons, Andrew
Go, Jowell
Golsorkhi, Tony
Chowdhury, Simon
Scher, Howard I.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[9] Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer
van Nuland, M.
Groenland, S. L.
Bergman, A. M.
Steeghs, N.
Rosing, H.
Venekamp, N.
Huitema, A. D. R.
Beijnen, J. H.
PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (02) : 244 - 251
[10] Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
Elias, Roy
Antonarakis, Emmanuel S.
TRANSLATIONAL CANCER RESEARCH, 2023, 12 (10) : 2448 - 2453

← 1 2 3 4 5 →